Form 8-K - Current report:
SEC Accession No. 0001193125-25-168614
Filing Date
2025-07-30
Accepted
2025-07-30 07:10:19
Documents
15
Period of Report
2025-07-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d24708d8k.htm   iXBRL 8-K 29020
2 EX-99.1 d24708dex991.htm EX-99.1 15825
6 GRAPHIC g24708g0520020555046.jpg GRAPHIC 2721
7 GRAPHIC g24708g0729220304437.jpg GRAPHIC 2384
  Complete submission text file 0001193125-25-168614.txt   176946

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vrdn-20250730.xsd EX-101.SCH 2856
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vrdn-20250730_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vrdn-20250730_pre.xml EX-101.PRE 11265
18 EXTRACTED XBRL INSTANCE DOCUMENT d24708d8k_htm.xml XML 3670
Mailing Address 221 CRESCENT STREET SUITE 103A WALTHAM MA 02453
Business Address 221 CRESCENT STREET SUITE 103A WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Filer) CIK: 0001590750 (see all company filings)

EIN.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)